Sustained response to pembrolizumab in recurrent perivascular epithelioid cell tumor with elevated expression of programmed death ligand: a case report

Peer Review reports

Original Submission
24 Feb 2021	Submitted	Original manuscript
29 May 2021	Reviewed	Reviewer Report - Krishna Sharan
1 Jun 2021	Reviewed	Reviewer Report - Ciniraj Raveendran
Resubmission - Version 2
	Submitted	Manuscript version 2
Publishing
2 Jun 2021	Editorially accepted
24 Jul 2021	Article published	10.1186/s13256-021-02997-x

Back to article page